PMID: 9541188Apr 16, 1998Paper

Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat

Breast Cancer Research and Treatment
S SinhaR J Santen

Abstract

Aromatase catalyzes the rate limiting step that converts androgens to estrogens. Postmenopausal women with hormone dependent breast cancer respond to first generation aromatase inhibitors such as aminoglutethimide with a marked suppression of circulating estradiol levels. In contrast, premenopausal women appear to be resistant to first generation aromatase inhibitors. The inability to block ovarian aromatase results from the low affinity of first generation inhibitors for the active site of the enzyme. Under these circumstances, the high substrate levels in the premenopausal ovary compete effectively with these inhibitors and do not allow binding of inhibitor to the active site of the enzyme. Second and third generation aromatase inhibitors with higher affinity for aromatase have now been developed and potentially could block ovarian aromatase. To test this possibility, we administered CGS 20267 (letrozole), a highly potent aromatase inhibitor, to cycling female rats. A dose dependent inhibition of uterine weight occurred with maximum effects produced by the 5 mg/kg/day dosage. During a period of 4 weeks, uterine weight was reduced to levels induced by ovariectomy. Ovarian tissue estradiol levels were inhibited by approximately...Continue Reading

References

May 1, 1990·Endocrine Reviews·R J SantenC Redmond
Dec 1, 1972·Endocrinology·E O ReiterG T Ross
Sep 1, 1980·The Journal of Clinical Endocrinology and Metabolism·R J SantenS A Wells
Jan 3, 1980·The New England Journal of Medicine·I C Henderson, G P Canellos
Jun 1, 1994·Endocrine Reviews·E R SimpsonM D Michael
Mar 1, 1993·The Journal of Steroid Biochemistry and Molecular Biology·K SchieweckM Lang

❮ Previous
Next ❯

Citations

Mar 10, 2007·Cell and Tissue Research·Fernanda Cristina Alcântara SantosSebastião Roberto Taboga
Dec 22, 2004·Current Oncology Reports·Lisa E Sokolowicz, William J Gradishar
Jun 9, 2005·The Journal of Steroid Biochemistry and Molecular Biology·James N Ingle, Vera J Suman
Sep 6, 2003·Steroids·Richard J Santen
Nov 25, 2003·The Journal of Steroid Biochemistry and Molecular Biology·B P HaynesA S Bhatnagar
Jun 13, 2003·The New England Journal of Medicine·Ian E Smith, Mitch Dowsett
May 1, 2012·Reproduction, Fertility, and Development·M Jimena YapuraGregg P Adams
May 29, 2002·Current Opinion in Obstetrics & Gynecology·Mohamed F Mitwally, Robert F Casper
Mar 4, 2003·Environmental Health Perspectives·Jürg A ZarnJosef R Schlatter
Dec 19, 2003·Reproductive Biomedicine Online·H Mousavi FatemiP Devroey
Apr 2, 2010·Fertility and Sterility·Simone FerreroValentino Remorgida
Jul 17, 2004·Acta Obstetricia Et Gynecologica Scandinavica·Oznur KaraerFaik Mümtaz Koyuncu
Sep 14, 2007·BJU International·Wei-Yu LinRobert M Levin
Jan 28, 2010·International Journal of Cancer. Journal International Du Cancer·Wei YueRichard Santen
May 15, 2015·Cell and Tissue Research·Anthony Mwakikunga, Margot J Hosie
Oct 30, 2016·Reproductive Toxicology·Gian Mario Tiboni, Adalisa Ponzano
May 23, 2008·Biology of Reproduction·Fernanda C A SantosSebastião R Taboga
Dec 12, 2003·Nature Reviews. Cancer·Stephen R D Johnston, Mitch Dowsett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
P CarliniF Cognetti
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
Yanfei L MaMasahiko Sato
© 2022 Meta ULC. All rights reserved